Literature DB >> 10993942

DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation.

Gary P Bembridge1, Nuria Rodriguez2, Regina Garcia-Beato2, Carolyn Nicolson3, Jose A Melero2, Geraldine Taylor1.   

Abstract

Significant protection against respiratory syncytial virus (RSV) infection was induced in mice vaccinated intramuscularly (i.m.) with DNA encoding the F or G protein of RSV. The amounts of IgG1 of IgG2a antibodies in mice immunized with DNA-G alone were similar. However, the antibody response in mice co-immunized with DNA-G and DNA encoding IL-4 (DNA-IL-4) was strongly biased towards IgG1. In contrast, the antibody response in mice co-immunized with DNA-G and DNA-IL-2, -IL-12 or-IFN-gamma was biased towards IgG2a. Mice vaccinated with DNA-F either alone or in combination with DNA encoding cytokines developed a predominant RSV-specific IgG2a response, which was most pronounced in mice co-immunized with DNA-F and DNA-IL-12 or -IFN-gamma. Vaccinated mice developed only a slightly enhanced pulmonary inflammatory response following RSV challenge. More significantly, and in contrast to mice scarified with recombinant vaccinia virus expressing the G protein, mice vaccinated i.m. with DNA-G did not develop pulmonary eosinophilia, even when the immune response was biased towards a Th2 response by co-administration of DNA-IL-4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993942     DOI: 10.1099/0022-1317-81-10-2519

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

Review 2.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

Review 3.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

4.  Novel recombinant DNA vaccine candidates for human respiratory syncytial virus: Preclinical evaluation of immunogenicity and protection efficiency.

Authors:  Mohamed A Farrag; Haitham M Amer; Peter Öhlschläger; Maaweya E Hamad; Fahad N Almajhdi
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

5.  Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats.

Authors:  Gabriella Cseke; David W Wright; Sharon J Tollefson; Joyce E Johnson; James E Crowe; John V Williams
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

6.  A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus.

Authors:  Wendy Fonseca; Makoto Ozawa; Masato Hatta; Esther Orozco; Máximo B Martínez; Yoshihiro Kawaoka
Journal:  Arch Virol       Date:  2013-12-01       Impact factor: 2.574

7.  DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.

Authors:  Mathieu Boxus; Marylène Tignon; Stefan Roels; Jean-François Toussaint; Karl Walravens; Marie-Ange Benoit; Philippe Coppe; Jean-Jacques Letesson; Carine Letellier; Pierre Kerkhofs
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

8.  Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus.

Authors:  Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Yu-Na Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Ki-Hye Kim; Min Kyoung Cho; Young-Tae Lee; You Ri Lee; Fu-Shi Quan; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

9.  Virus-like nanoparticle and DNA vaccination confers protection against respiratory syncytial virus by modulating innate and adaptive immune cells.

Authors:  Eun-Ju Ko; Young-Man Kwon; Jong Seok Lee; Hye Suk Hwang; Si-Eun Yoo; Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Min Kyoung Cho; You Ri Lee; Fu-Shi Quan; Jae-Min Song; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Nanomedicine       Date:  2014-08-08       Impact factor: 5.307

10.  RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

Authors:  Hongzhuan Wu; Vida A Dennis; Shreekumar R Pillai; Shree R Singh
Journal:  Virus Res       Date:  2009-06-21       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.